SCHEMBL3295342

SCHEMBL3295342

Cc1c(Cl)cccc1S(=O)(=O)Nc1cc2c(nc1OCc1ccc(Cl)c(OCCN(C)C)c1)CCN(C)C2

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 4/20 0.36
AKT1 P31749 1/20 0.36
MYLK Q15746 1/20 0.36
MAPK14 Q16539 1/20 0.36
HSD11B1 P28845 5/20 0.35
HSD17B1 P14061 1/20 0.35
HSD17B2 P37059 1/20 0.35
SLC40A1 Q9NP59 1/20 0.35
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
POLB P06746 1/20 0.33
AXL P30530 1/20 0.32
ALK Q9UM73 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3296954 0.94 CCR4 (0.44) CCR4AKT1MYLKMAPK14HSD11B1
SCHEMBL3292075 0.94 CCR4 (0.39) CCR4
SCHEMBL3294186 0.94 ALDH1A1 (0.37) CCR4HTTNPSR1ALDH1A1POLB
SCHEMBL3294684 0.90 CCR4 (0.39) CCR4AKT1MYLKMAPK14HSD11B1
SCHEMBL3296435 0.90 AKT1 (0.37) CCR4AKT1MYLKMAPK14HSD11B1
SCHEMBL3293849 0.90 AKT1 (0.39) CCR4AKT1MYLKMAPK14HSD11B1
SCHEMBL3290915 0.89 SLC40A1 (0.40) CCR4AKT1MYLKMAPK14HSD11B1
SCHEMBL3294350 0.89 UTS2R (0.39) CCR4AXL
SCHEMBL3293831 0.88 CCR4 (0.48) CCR4ALDH1A1GAASMN1; SMN2POLB
SCHEMBL3300382 0.88 PIK3R1 (0.37) CCR4AKT1MYLKMAPK14HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100266539-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-10-21 US disclosed
US-7732442-B2 Chemokine receptor antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-06-08 US disclosed
US-20070254886-A1 Chemokine Receptor Antagonist and Medical Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-11-01 US disclosed
EP-1661889-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100266539-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF CCR5, CCR4, CCR1 CCR4 2/4885AKT1 714/4885MYLK 3704/4885
US-20070254886-A1 Chemokine Receptor Antagonist and Medical Use Thereof CCR5, CCR4, CCR1 CCR4 2/4885AKT1 714/4885MYLK 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.